Preclinical tests show promise against primary effusion lymphoma

06/27/2013 | InfectionControlToday.com

A study in the journal Oncogene found that a class of drugs called BET bromodomain inhibitors can effectively treat primary effusion lymphoma, a rare and aggressive blood cancer. The disease is caused by infection with Kaposi's sarcoma-associated herpes virus and is most commonly seen among patients with HIV. Inhibitors targeting the BRD4 protein halted the growth of PEL cells in laboratory and animal tests.

View Full Article in:

InfectionControlToday.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA